Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F.
Bello Roufai D, et al. Among authors: cottu p.
Oncogene. 2023 Jun;42(23):1951-1956. doi: 10.1038/s41388-022-02585-3. Epub 2023 Jan 7.
Oncogene. 2023.
PMID: 36611120